Business Description
Imunon Inc. is a clinical-stage biotechnology company based in Lawrenceville, New Jersey, focused on developing treatments that use the body's immune system to fight cancer and infectious diseases. Its most advanced program, IMNN-001, is a DNA-based therapy for ovarian cancer currently in Phase II trials, while several other candidates targeting COVID-19, Lassa virus, and melanoma are in earlier stages of development. The company's work centers on a proprietary non-viral DNA platform designed to deliver genetic instructions directly to cells, avoiding the need for viral carriers. Founded in 1982 and formerly known as Celsion Corporation, the company adopted its current name in 2022.
